IGHI: One Way to Diagnose Hepatic Insufficiency the First Postoperative Day After Resection: Prospective Cohort Study

Sponsor
Castilla-La Mancha Health Service (Other)
Overall Status
Completed
CT.gov ID
NCT04570800
Collaborator
(none)
44
27

Study Details

Study Description

Brief Summary

Introduction: Hepatic insufficiency is a complication that puts the life of the patient undergoing resective surgery at risk. Thus, the diagnosis should be made early. The current gold standard allows its diagnosis on the fifth postoperative day.

Indocyanine green is a water soluble dye. When administered intravenously, it binds to plasma proteins and it is removed unchanged by bile, without experiencing enterohepatic recirculation, which allows estimating the function of hepatocytes and the function of hepato-splacnic flow. There is a measurement system named "Non-invasive liver function monitor" (LiMONĀ®, PULSION Medical Systems, Munich, Germany), which allows the measurement of indocyanine green clearance at the patient's bedside.

Justification: The use of indocyanine green plasma disappearance during the perioperative period tries to know the exact value of the hepatic function in the most real conditions, when the excision has been performed, thus giving the investigators the actual value of the unresected liver. This allows te investigators to estimate the risk of hepatic insufficiency development that can lead to hepatic failure. Due to the characteristics of the test, it could get reliable results earlier than the current "gold standard " (50:50 Criteria on the 5th postoperative day).

Hypotheses and Objectives: The investigators hypothesized that the determination of the hepatic reserve by identifying the indocyanine plasma clearance in real time after hepatic parenchymal resection could lead to a more accurate and earlier statement of the hepatic reserve than current tests.

The aim of the study is to determine the usefulness of indocyanine green in the perioperative period to early diagnosis of hepatic failure.

Materials and Methods: A prospective observational post-authorization study (EPA-SP) is performed to study de usefulness of indocyanine green. The study was approved by the Ethics and Clinical Research Committee of the University General Hospital of Ciudad Real. Surgical patients scheduled for liver surgery, who agreed to be included in the study and signed an informed consent, were included in the study over a two-year period, after having understood the study objectives and its possible complications.

Measurements were performed with the LiMONĀ® monitor prior to liver resection and on the first postoperative day to patients undergoing liver resection surgery and compared with gold standard.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    44 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    One Way to Diagnose Hepatic Insufficiency the First Postoperative Day After Resection: Prospective Cohort Study
    Actual Study Start Date :
    Dec 1, 2014
    Actual Primary Completion Date :
    Jun 1, 2015
    Actual Study Completion Date :
    Mar 1, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients wich the plasma removal rate of Indocianin Green at 24h of surgery correlates with the existence of liver failure on the 5th postoperative day [5 days]

      Number of patients wich the plasma removal rate of Indocianin Green at 24h of surgery correlates with the existence of liver failure on the 5th postoperative day

    Secondary Outcome Measures

    1. Number of patients wich the plasma removal rate of Indocianin Green at 24h of surgery correlates with the existence of liver failure on the 3th postoperative day [3 days]

      Number of patients the plasma removal rate of Indocianin Green at 24h of surgery correlates with the existence of liver failure on the 3th postoperative day

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients susceptible of receiving Surgical treatment

    • Liver Disease with Surgical Indication

    • Adulthood

    • Accept Inclusion

    Exclusion Criteria:
    • History of Hypersensitivity to Indocyanine Green or Iodine

    • Thyroid Pathology

    • Underage Status

    • Pregnant

    • Irresectable Tumors

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Castilla-La Mancha Health Service

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Castilla-La Mancha Health Service
    ClinicalTrials.gov Identifier:
    NCT04570800
    Other Study ID Numbers:
    • VBG-IND-2014-01
    First Posted:
    Sep 30, 2020
    Last Update Posted:
    Oct 5, 2020
    Last Verified:
    Sep 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Castilla-La Mancha Health Service
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 5, 2020